Publications by authors named "Martha Zapata-Tarres"
Rearrangements and overexpression of are hallmarks of poor outcomes in -like B-ALL, and overexpression is a high-risk marker in T-ALL. However, alterations in pediatric hematologic malignancies other than B-ALL have not been reported. In this study, we analyzed the overexpression, rearrangements ( and ), activation (pSTAT5 and pERK), and the expression of dominant-negative isoforms (Ik6 and Ik8), implied in dysregulation, in 16 pediatric patients (AML, = 9; T-ALL, = 3; LBL, = 2; HL, = 1; cytopenia, = 1).
View Article and Find Full Text PDFv-myb avian myeloblastosis viral oncogene homolog expression is a potential molecular diagnostic marker for B-cell acute lymphoblastic leukemia.
Asia Pac J Clin Oncol
February 2021
Background: B-cell acute lymphoblastic leukemia (B-ALL) is the most commonly diagnosed childhood malignancy worldwide and is especially common in Mexico. Additionally, the number of cases has increased in recent years. Thus, it is very important to develop molecular strategies to diagnose leukemia.
View Article and Find Full Text PDFArticle Synopsis
- B-cell acute lymphoblastic leukemia is the most common cancer in children, especially in Mexico, with over 30% of patients facing relapse and poor outcomes despite a high five-year survival rate.
- Research into gene expression profiles has identified certain transcripts that can help predict disease prognosis, particularly focusing on the ZNF695 gene, which has multiple transcript variants due to alternative splicing.
- In studies, the ZNF695 variants were found to be predominantly expressed in leukemia patients' bone marrow, and notably, the expression levels of long noncoding RNA ZNF695 were linked to survival rates.
Ovarian fibrosarcomas are extremely rare tumors with little genomic information available to date. In the present report we present the tumoral exome and transcriptome and the germinal exome of an ovarian fibrosarcoma from a 9-years old child. We found a paucity of mutations (0.
View Article and Find Full Text PDFUnlabelled: Amifostine has emerged as a pancytoprotectant shown protection against nephrotoxicity, neurotoxicity and ototoxicity in preclinical studies.
Methods: We designed a prospective comparative randomized trial to evaluate the cytoprotective effects of amifostine in patients with osteosarcoma receiving cisplatin and doxorrubicin. Patients were evaluated for renal, hearing and cardiac toxicity.